Health Plan and PBM Cost Mitigation Strategies

Member Price
Non-Member Price

In this CCA healthcare series webinar, presenters discuss strategies that health plans and pharmacy benefits managers are using to manage these high cost treatments. In recent years, the number of high cost pharmaceutical treatments for a variety of conditions has been increasing. These drugs typically categorized as specialty drugs include infusion drugs, biologics, oncology, and gene therapy treatments for both common and relatively rare conditions. 


Dr. Patrick P. Gleason, PharmD, BCPS, FCCP, FAMCP

Prime Therapeutics, LLC

Ian M. Smith


Kali Schweitzer PharmD

Milliman Inc.

Mr. David M. Tuomala



CPD Credit: 1.50 EA Core Credit: EA Ethics Credit: EA Non-Core Credit: EA Formal Credit: